Logo image of CELU

CELULARITY INC-A (CELU) Stock Price, Quote, News and Overview

NASDAQ:CELU - Nasdaq - US1511902041 - Common Stock - Currency: USD

1.595  +0.02 (+1.53%)

CELU Quote, Performance and Key Statistics

CELULARITY INC-A

NASDAQ:CELU (5/2/2025, 8:00:00 PM)

1.595

+0.02 (+1.53%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.22
52 Week Low1
Market Cap35.86M
Shares22.48M
Float9.95M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-28 2025-07-28/amc
IPO05-23 2019-05-23


CELU short term performance overview.The bars show the price performance of CELU in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

CELU long term performance overview.The bars show the price performance of CELU in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CELU is 1.595 USD. In the past month the price increased by 4.25%. In the past year, price decreased by -51.52%.

CELULARITY INC-A / CELU Daily stock chart

CELU Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About CELU

Company Profile

CELU logo image Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 120 full-time employees. The company went IPO on 2019-05-23. The company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).

Company Info

CELULARITY INC-A

170 Park Ave

Florham Park NEW JERSEY US

Employees: 120

CELU Company Website

CELU Investor Relations

Phone: 19087682170

CELULARITY INC-A / CELU FAQ

What is the stock price of CELULARITY INC-A today?

The current stock price of CELU is 1.595 USD. The price increased by 1.53% in the last trading session.


What is the ticker symbol for CELULARITY INC-A stock?

The exchange symbol of CELULARITY INC-A is CELU and it is listed on the Nasdaq exchange.


On which exchange is CELU stock listed?

CELU stock is listed on the Nasdaq exchange.


What is CELULARITY INC-A worth?

CELULARITY INC-A (CELU) has a market capitalization of 35.86M USD. This makes CELU a Nano Cap stock.


How many employees does CELULARITY INC-A have?

CELULARITY INC-A (CELU) currently has 120 employees.


What are the support and resistance levels for CELULARITY INC-A (CELU) stock?

CELULARITY INC-A (CELU) has a support level at 1.56 and a resistance level at 1.64. Check the full technical report for a detailed analysis of CELU support and resistance levels.


Is CELULARITY INC-A (CELU) expected to grow?

The Revenue of CELULARITY INC-A (CELU) is expected to decline by -68.68% in the next year. Check the estimates tab for more information on the CELU EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CELULARITY INC-A (CELU) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CELULARITY INC-A (CELU) stock pay dividends?

CELU does not pay a dividend.


When does CELULARITY INC-A (CELU) report earnings?

CELULARITY INC-A (CELU) will report earnings on 2025-07-28, after the market close.


What is the Price/Earnings (PE) ratio of CELULARITY INC-A (CELU)?

CELULARITY INC-A (CELU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.52).


What is the Short Interest ratio of CELULARITY INC-A (CELU) stock?

The outstanding short interest for CELULARITY INC-A (CELU) is 16.53% of its float. Check the ownership tab for more information on the CELU short interest.


CELU Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CELU. When comparing the yearly performance of all stocks, CELU is a bad performer in the overall market: 88.81% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CELU Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CELU. CELU has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CELU Financial Highlights

Over the last trailing twelve months CELU reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS increased by 85.54% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -27.21%
ROE -202.85%
Debt/Equity 2.47
Chartmill High Growth Momentum
EPS Q2Q%85.29%
Sales Q2Q%145.54%
EPS 1Y (TTM)85.54%
Revenue 1Y (TTM)225.94%

CELU Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to CELU. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -62.86% and a revenue growth -68.68% for CELU


Ownership
Inst Owners14.98%
Ins Owners16.73%
Short Float %16.53%
Short Ratio12.29
Analysts
Analysts82.86
Price TargetN/A
EPS Next Y-62.86%
Revenue Next Year-68.68%